<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="100 antiviral drugs have been approved since the approval of" exact="idoxuridine" post="in 1963 (an antiâ€�herpes virus drug), these molecules are"/>
 <result pre="of multiple proâ€�inflammatory mediators, including TNFÎ±, interleukin (IL)â€�1, ILâ€�6, and" exact="nitric oxide" post="by activated monocytes/macrophages.22 Consistent with EVD pathogenesis, high levels"/>
 <result pre="antiviral efficacy in vitro or in vivo. Combining favipiravir and" exact="ribavirin" post="in Lassa fever Favipiravir was also reported to have"/>
 <result pre="Indeed. several in vitro studies and mice studies showed that" exact="ribavirin" post="may potentiate the efficacy of favipiravir against various RNA"/>
 <result pre="Lassa fever virus infection.78 In order to better understand how" exact="ribavirin" post="may potentiate the efficacy of favipiravir in mice, we"/>
 <result pre="In order to gain information on the potential role of" exact="ribavirin" post="on loss cell death, we assumed that the level"/>
 <result pre="in HCV to quantify the levels of hepatocytes injury using" exact="alanine" post="aminotransferase dynamics79: d A d t = s x"/>
 <result pre="infected cells. We assumed four potential mechanisms of action for" exact="ribavirin" post="that could (i) act as a mutagen limiting the"/>
 <result pre="Our analyses did not find a statistically significant effect of" exact="ribavirin" post="in reducing viral production, however, the best description to"/>
 <result pre="to the data was obtained by assuming an effect of" exact="ribavirin" post="in preventing infected cells from dying. This possibly explains"/>
 <result pre="also explain the viral plateau observed at peak viremia in" exact="ribavirin" post="monotherapy group.80 Thus, our model suggested that ribavirin did"/>
 <result pre="viremia in ribavirin monotherapy group.80 Thus, our model suggested that" exact="ribavirin" post="did not act much as a direct antiviral against"/>
 <result pre="virus, it is unlikely that the combination of favipiravir and" exact="ribavirin" post="is relevant against EBOV, as no gain in terms"/>
 <result pre="new epidemic clusters arising. Likewise, the combination of favipiravir and" exact="ribavirin" post="in Lassa virus hemorrhagic fever could be of relevance"/>
 <result pre="9Oestereich, L.et alEfficacy of favipiravir alone and in combination with" exact="ribavirin" post="in a lethal, immunocompetent mouse model for Lassa fever."/>
 <result pre="66Dixit, N.M., Laydenâ€�Almer, J.E., Layden, T.J. &amp;amp; Perelson, A.S.Modelling how" exact="ribavirin" post="improves interferon response rates in hepatitis C virus infection."/>
 <result pre="kinetic and modeling analyses indicate similar time to cure among" exact="sofosbuvir" post="combination regimens with daclatasvir, simeprevir or ledipasvir. J. Hepatol.64,"/>
 <result pre="similar time to cure among sofosbuvir combination regimens with daclatasvir," exact="simeprevir" post="or ledipasvir. J. Hepatol.64, 1232â€&quot;1239 (2016).26907973 68Madelain, V.et alEbola"/>
 <result pre="in macaques. Emerg. Infect. Dis.24, 1696â€&quot;1699 (2018).29882740 77Westover, J.B.et alLowâ€�dose" exact="ribavirin" post="potentiates the antiviral activity of favipiravir against hemorrhagic fever"/>
 <result pre="fever viruses. Antiviral Res.126, 62â€&quot;68 (2016).26711718 78Raabe, V.N.et alFavipiravir and" exact="ribavirin" post="treatment of epidemiologically linked cases of Lassa fever. Clin."/>
 <result pre="Laydenâ€�Almer, J., Powers, K.A., Layden, T.J. &amp;amp; Perelson, A.S.Dynamics of" exact="alanine" post="aminotransferase during hepatitis C virus treatment. Hepatology38, 509â€&quot;517 (2003).12883496"/>
</results>
